首頁 › 子宮內膜癌 › 德克薩斯州 › Fort Worth
Fort Worth, TX 的 子宮內膜癌 臨床試驗
12 項針對 子宮內膜癌 的研究正在 Fort Worth（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- START Center for Cancer Research - Texas, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- START Center for Clinical Research, Fort Worth
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
招募中2 期
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
招募中1/2 期
- START Dallas Fort Worth, Fort Worth
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
招募中3 期
- Texas Oncology - DFW ( Site 8004), Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Start - Dfw, Fort Worth
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
招募中3 期
- USOR - Texas Oncology - Dallas Fort Worth (DFW), Fort Worth
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
招募中3 期
- Research Site, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Texas Oncology, Fort Worth
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- UT Southwestern - Simmons Cancer Center - Fort Worth, Fort Worth
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
招募中1 期
- START Dallas Fort Worth, LLC, Fort Worth
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
招募中2/3 期
- Texas Oncology-Fort Worth Cancer Center, Fort Worth
其他城市的 子宮內膜癌 試驗
- Houston, TX68 項研究
- New York City, NY52 項研究
- Boston, MA50 項研究
- Arlington, VA39 項研究
- Nashville, TN38 項研究
- Los Angeles, CA34 項研究
- St. Louis, MO29 項研究
- Philadelphia, PA28 項研究
- San Antonio, TX27 項研究
- Columbus, OH25 項研究
- Chicago, IL25 項研究
- Oklahoma City, OK25 項研究
Fort Worth 的其他研究
- 非小細胞肺癌18 項研究
- 卵巢癌17 項研究
- 乳癌12 項研究
- 癌症（所有類型）9 項研究
- 前列腺癌9 項研究
- 三陰性乳癌7 項研究
- 黃斑部病變7 項研究
- 潰瘍性結腸炎7 項研究
- 腎臟癌（腎細胞癌）7 項研究
- 心臟衰竭7 項研究
- 轉移性癌症7 項研究
- 大腸直腸癌7 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。